Opus Genetics Files Proxy Materials

Ticker: IRD · Form: DEFA14A · Filed: Apr 11, 2025 · CIK: 1228627

Sentiment: neutral

Topics: proxy-statement, corporate-governance, filing-update

TL;DR

Opus Genetics (OPUS) filed proxy docs, shareholders vote soon.

AI Summary

Opus Genetics, Inc. filed a Definitive Additional Materials proxy statement on April 11, 2025. This filing relates to the company's solicitation of proxies for its upcoming shareholder meeting. The company was formerly known as Ocuphire Pharma, Inc. before changing its name on November 9, 2020.

Why It Matters

This filing is important for shareholders as it contains information and proposals that will be voted on at the company's shareholder meeting, impacting corporate governance and future decisions.

Risk Assessment

Risk Level: low — This filing is a routine proxy statement and does not contain new financial information or significant corporate actions that would inherently increase risk.

Key Players & Entities

FAQ

What is the purpose of this DEFA14A filing?

This filing is for Definitive Additional Materials, indicating Opus Genetics, Inc. is providing supplemental information to shareholders in connection with the solicitation of proxies.

When was Opus Genetics, Inc. previously known by another name?

Opus Genetics, Inc. was formerly known as Ocuphire Pharma, Inc., with the name change occurring on November 9, 2020.

What is the Central Index Key (CIK) for Opus Genetics, Inc.?

The Central Index Key for Opus Genetics, Inc. is 0001228627.

What is the Standard Industrial Classification (SIC) code for Opus Genetics, Inc.?

The Standard Industrial Classification code for Opus Genetics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

What is the filing date of this DEFA14A document?

This DEFA14A document was filed on April 11, 2025.

Filing Details

This Form DEFA14A (Form DEFA14A) was filed with the SEC on April 11, 2025 regarding Opus Genetics, Inc. (IRD).

View full filing on EDGAR

View Full Filing

View this DEFA14A filing on SEC EDGAR

View on Read The Filing